Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Change in Accured Expenses: 2018-2025

Historic Change in Accured Expenses for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Sep 2025 value amounting to -$5.4 million.

  • Arcturus Therapeutics Holdings' Change in Accured Expenses fell 66.37% to -$5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.2 million, marking a year-over-year decrease of 691.77%. This contributed to the annual value of $5.9 million for FY2024, which is 1108.84% up from last year.
  • According to the latest figures from Q3 2025, Arcturus Therapeutics Holdings' Change in Accured Expenses is -$5.4 million, which was up 10.58% from -$6.1 million recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' Change in Accured Expenses ranged from a high of $10.6 million in Q2 2021 and a low of -$9.4 million during Q4 2021.
  • Moreover, its 3-year median value for Change in Accured Expenses was -$454,000 (2023), whereas its average is -$1.3 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first surged by 465.08% in 2021, then plummeted by 2,174.66% in 2025.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Change in Accured Expenses (Quarterly) stood at -$9.4 million in 2021, then soared by 178.73% to $7.4 million in 2022, then crashed by 61.65% to $2.8 million in 2023, then surged by 130.15% to $6.6 million in 2024, then plummeted by 66.37% to -$5.4 million in 2025.
  • Its Change in Accured Expenses was -$5.4 million in Q3 2025, compared to -$6.1 million in Q2 2025 and -$8.2 million in Q1 2025.